Avastin demonstrated proven efficacy in multiple OC indications

Avastin plus chemotherapy demonstrated a superior median PFS benefit in stage III/IV ovarian cancer after primary surgery

In the GOG-0218 study, Avastin plus chemotherapy followed by single-agent Avastin increased median PFS by 6.2 months (18.2 months vs 12.0 months) vs chemotherapy alone (HR=0.62 [95% CI, 0.52–0.75], P<0.0001).[1]

In psOC, Avastin plus chemotherapy increased PFS (OCEANS) and OS (GOG-0213) in platinum-sensitive ovarian cancer[1]

  • In the OCEANS study, median PFS was 12.4 months with Avastin plus chemotherapy vs 8.4 months with placebo plus chemotherapy (HR=0.46 [95% CI, 0.37–0.58], P<0.0001)
  • In the GOG-0213 study, median OS was 42.6 months with Avastin plus chemotherapy vs 37.3 months with chemotherapy alone (HR=0.84 [95% CI, 0.69–1.01 (IVRS)]; HR=0.82 [95% CI, 0.68–0.996 (eCRF)]

In prOC, Avastin plus chemotherapy demonstrated PFS results in patients who received no more than 2 prior chemotherapy regimens[1]

In the AURELIA study, median PFS was 6.8 months (95% CI, 5.6–7.8) with Avastin plus chemotherapy vs 3.4 months (95% CI, 2.1–3.8) with chemotherapy alone (HR=0.38 [95% CI, 0.30–0.49], P<0.0001).

OC=ovarian cancer; PFS=progression-free survival; GOG=Gynecologic Oncology Group; HR=hazard ratio; CI=confidence interval; psOC=platinum-sensitive ovarian cancer; OS=overall survival; IVRS=interactive voice response system; eCRF=electronic case report form; prOC=platinum-resistant ovarian cancer.